BioSpace News Archive

Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg versus placebo.

Designation for Patients Unfit for Curative Intent Therapy

BPN14770 is a selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype.

DURATION-7 study results showed significant HbA1c reduction when BYDUREON was added to insulin glargine therapy vs insulin glargine alone

Partnership is part of MetaBank’s continued investment in consumer lending via its total solution platform for marketplace lending

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.

Kleo Pharmaceuticals Inc. announced the appointment of Luca Rastelli PhD, as Chief Scientific Officer, effective immediately and reporting to Doug Manion, CEO. Dr. Rastelli will lead all aspects of R&D for the company and serve as the scientific external face of Kleo Pharmaceuticals to the investor, scientific, medical and patient communities.

Ciox announces its partnership with Trevelino/Keller, a full-service public relations and digital marketing agency.

Company’s Solution is a MicroRNA Biomarker Detecting Patient’s Risk for Relapse at Diagnosis

Melinda Egging has been named president of The Denver Hospice, effective immediately.